彩客化學(01986.HK)擬投資4,000萬人幣於BPDA產品生產項目
彩客化學(01986.HK)公佈,其附屬山東彩客擬於中國山東省東營市山東彩客現有場地內,投資新建3, 3’, 4, 4’-聯苯四甲酸二酐產品(BPDA產品)生產線的項目,且正在申請政府機關的備案證明。該項目總投資約爲4,000萬元人民幣,整體規劃爲新建BPDA產品產能每年500噸。
BPDA產品爲生產聚(酉先)亞胺(一類具有(酉先)亞胺重複單元的聚合物)產品的重要原料。聚(酉先)亞胺是一種廣泛用於半導體、微電子、航空航天、高鐵、太陽能電池及鋰電池等領域的高性能高分子化合物。
公司計劃於2022年6月底前完成該項目的建設。該項目投資資金以內部資金或通過銀行融資或股權融資方式滿足。目前集團並未確定任何股權籌資計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.